Clinical trials: Inhalation
Diabetes Mellitus, Type 1
Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents
To assess the safety and efficacy of Exubera on pulmonary function and glycemic control in subjects ages 6-17 over a 1 year period.
- Trial name
- NCT00479258
- Testing
- Inhaled insulin (Exubera), Subcutaneous Insulin (subject's prescribed)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Pfizer
Asthma
A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma
The primary objective will be to compare the Eurofarma and Alenia formulations regarding their impact on the pulmonary function of mild to moderate persistent asthma patients and the secondary objective will be to compare the…
- Trial name
- UNIK (NCT01167010)
- Testing
- Formoterol/Budesonide, Foraseq, Alenia
- Where
- 5 sites in Brazil
- Volunteers
- 552 people
- Sponsor
- Eurofarma Laboratorios S.A.
Cystic Fibrosis
Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis
To evaluate the change in forced expiratory volume (FEV1) from baseline to Day 28-30 between Cipro Inhale-treated and placebo-treated subjects after a 4-week treatment period.
- Trial name
- NCT00645788
- Testing
- Ciprofloxacin (Cipro Inhale, BAYQ3939)
- Where
- 86 sites in United States, Australia and 7 more
- Volunteers
- 288 people
- Sponsor
- Bayer
Asthma
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily each evening with fluticasone furoate inhalation powder administered alone once…
- Trial name
- NCT01134042
- Testing
- Fluticasone Furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Fluticasone Propionate Inhalation Powder
- Where
- 71 sites in United States, Germany and 4 more
- Volunteers
- 587 people
- Sponsor
- GlaxoSmithKline
Asthma
Long-acting Beta Agonist Step Down Study
This study is a 56-week, multi-center, blinded, randomized, double-masked parallel group comparative effectiveness study of approaches to stepping down therapy for patients with well-controlled asthma treated with combination ICS…
- Trial name
- LASST (NCT01437995)
- Testing
- Fluticasone/Salmeterol Diskus, Fluticasone Diskus
- Where
- 19 sites in United States
- Volunteers
- 459 people
- Sponsor
- Johns Hopkins University
Constrictive Bronchiolitis, Bronchiolitis Obliterans
Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome
Background: Bronchiolitis obliterans or bronchiolitis obliterans syndrome is a lung disorder that occurs as a complication of either lung transplantation or bone marrow/blood stem cell transplantation.
- Conditions
- Constrictive Bronchiolitis, Bronchiolitis Obliterans, Graft vs Host Disease, Bronchiolitis, Exudative
- Trial name
- NCT01287078
- Testing
- Cyclosporine Inhalation Solution
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Exercise-induced Bronchoconstriction (EIB)
The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)
This study will see if there is a change in breathing after exercising when the child receives study drug ( montelukast or placebo).
- Trial name
- NCT00534976
- Testing
- Comparator: montelukast sodium
- Volunteers
- 364 people
- Sponsor
- Organon and Co
Cystic Fibrosis (CF)
Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to…
- Trial name
- NCT00677365
- Testing
- MP-376
- Where
- 50 sites in United States, Germany and 1 more
- Volunteers
- 151 people
- Sponsor
- Amgen
Asthma
Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma
This study is designed to explore lung function effects of two doses of indacaterol acetate, 75 μg and 150 μg, in pediatric asthma patients 6-11 years old, and to compare the systemic exposure to indacaterol in plasma with…
- Trial name
- NCT02892019
- Testing
- Indacaterol acetate 75 μg, Indacaterol acetate 150 μg
- Where
- 29 sites in Belgium, Colombia and 9 more
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
PAH
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
This was a multi-center, open-label, safety, tolerability and pharmacokinetic study of oral treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who were (1) transitioning from parenteral Remodulin therapy; (2)…
- Trial name
- NCT02276872
- Testing
- oral treprostinil
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- United Therapeutics
Asthma
A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA
The purpose of this study is to characterize the safety profile of benralizumab administration in asthma patients who have completed one of the three predecessor studies: D3250C00017, D3250C00018 or D3250C00020.
- Trial name
- BORA (NCT02258542)
- Testing
- Benralizumab
- Where
- 429 sites in United States, Argentina and 22 more
- Volunteers
- 2,133 people
- Sponsor
- AstraZeneca
Asthma in Children, Medication Adherence
Financial Incentives to Improve Asthma
The aim of this pilot randomised controlled trial is to assess the effectiveness of a short-term financial incentives intervention at bringing about behaviour change, namely short-medium term improvements in inhaled…
- Trial name
- FINA (NCT05322044)
- Testing
- Financial incentives
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Imperial College London
Pulmonary Hypertension
Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide
Acute secondary pulmonary hypertension (PH) often leads to dysfunction of the right ventricle (RV) and can be a significant cause of patient morbidity and mortality.
- Trial name
- NCT02170519
- Testing
- Inhaled Iloprost
- Volunteers
- 27 people
- Sponsor
- Duke University
Asthma
HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily with fluticasone propionate/salmeterol administered twice daily in adolescent…
- Trial name
- NCT01147848
- Testing
- Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone propionate/salmeterol Inhalation Powder
- Where
- 63 sites in United States, Argentina and 4 more
- Volunteers
- 810 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis
International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF1 (NCT00112359)
- Testing
- AZLI 75 mg three times a day (TID)
- Where
- 53 sites in United States, Australia and 2 more
- Volunteers
- 166 people
- Sponsor
- Gilead Sciences
Asthma
Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study
The purpose of this study is to evaluate the long-term safety of fluticasone furoate/GW642444
- Trial name
- NCT01018186
- Testing
- Fluticasone Furoate/GW642444, Fluticasone propionate
- Where
- 47 sites in United States, Germany and 2 more
- Volunteers
- 503 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma
The primary objective of this trial is to evaluate the efficacy and safety of tiotropium 1.25 mcg (2 actuations of 0.625 mcg), tiotropium 2.5 mcg (2 actuations of 1.25 mcg) and tiotropium 5 mcg (2 actuations of 2.5 mcg) once…
- Trial name
- NCT01122680
- Testing
- Tiotropium bromide
- Where
- 19 sites in United States, Germany and 3 more
- Volunteers
- 105 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1
The primary objective of this trial is to assess the efficacy, safety and pharmacokinetics of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler versus placebo in adolescents and adult patients with cystic…
- Trial name
- NCT04059094
- Testing
- BI 1265162
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 52 people
- Sponsor
- Boehringer Ingelheim
Asthma
Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma
This study is being conducted to compare the pharmacodynamics (bronchodilation, onset and duration of action), of a single dose of formoterol fumarate in combination with mometasone furoate to placebo in children of 5-11 years…
- Trial name
- NCT00746330
- Testing
- Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D)
- Where
- 9 sites in United States, Colombia and 1 more
- Volunteers
- 32 people
- Sponsor
- Novartis
Asthma
Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma
Specific Aim: To determine whether a prescription for Inhaled Corticosteroids (ICS) added to standard Emergency Department (ED) discharge therapy for young children with persistent asthma symptoms increases ICS use and improves…
- Trial name
- NCT00294398
- Testing
- ICS Prescription + Standard Asthma ED Discharge Therapy, Standard Asthma ED Discharge Therapy
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Children's Hospital of Philadelphia